The FDA approved two new indications for trastuzumab deruxtecan (Enhertu) to treat early-stage HER2-positive breast cancer in both neoadjuvant and adjuvant settings.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Blockbuster Drug Gets Breast Cancer Approvals in Curative Setting | MedPage Today
HER2-Positive Early Breast Cancer Disease type
67.3% With New Regimen pCR rate
92.4% Vs 83.7% Kadcyla 3-year survival
67.3% pCR rate
0.47 hazard ratio
92.4% 3-year survival